Home / Resources / Interview with the new Managing Director of Symeres Groningen

Published: 01.11.2023

Interview with the new Managing Director of Symeres Groningen

On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site. Melloney, as an introduction, can you tell us a little about yourself?  

Sure! I was born in Groningen as the eldest child of seven children. After a few years in Groningen we moved as a family to Winsum, and later on to Zuidlaren, in Drenthe. Years later, I made the decision to return to Zuidlaren with my own family, and I still live there with my husband and two daughters. Our eldest daughter is 13 years old and attending a high school in Groningen, and our youngest is almost 11.

For myself, I am going back to my roots by working in Groningen again. I also love to read, and my house is filled with lots of books, really lots of books, and not just scientific ones!

Living in Zuidlaren, we make the most of outdoor life as a family by enjoying the opportunity to go walking and cycling. Finally, I do attempt to cook and bake. In the kitchen, I don’t like to experiment. Being a pharmacist at heart, I like to follow recipes precisely!

Can you briefly summarize how your professional career has developed?

My career started in Groningen, first studying pharmacy at the local university. What became clear to me quickly, was that I was more attracted to research, although that was not that common at the time. That is why I chose to do my PhD in pharmacy in Groningen, and I really enjoyed bringing new technologies to this field of research, which was quite an uncommon practice at the time I was studying.

After my PhD, I stayed on as a postdoc, and taught for a year, and then moved out of the academic world.

Nineteen years ago, I joined Ardena in Assen, which was called ABL then. I joined the company as Project Manager, focusing on bioanalysis of small and large molecules. I was involved in growing the company, and I spent several years developing analytical methods we could use within the company.

Eventually, I moved to the position of Head of the Project Management Department, collaborating closely with our sales team. Four years ago, the then Managing Director decided to retire, and I was offered the opportunity to move into his role, which I did. In the past five years, we have been able to double the revenue and grow the team to 100 people.

What was your main motivation for coming to Symeres?

That is a good question; lots of people have asked me that in the past months.

I do see a lot of parallels between my former job and the Managing Director role in Groningen. Actually, I was not looking for something new, but when I was approached for this job, I started to think about it very seriously and I got more and more enthusiastic.

What triggered me to make the switch was that it offered me something new. I like to get out of my comfort zone and that is what this job certainly has to offer. To be honest, it was not a rational decision, but it felt good and still feels good, so I just chose to accept the role and make a major change after 19 years with the same company.

What do you, as a leader of people, believe are essential values that you would like to bring or see in the organization?

I know the direction I want to go, and where I want the company to go. For this, excellent teamwork across all our projects is one of the essentials. I am direct and that is also how I like to work. I prefer clear and open communication.

Another thing is goal-oriented working; I set goals for myself and for the organization. It is important for me that we are clear and transparent with each other, challenge each other, and keep things moving forward.

What gives you energy?

Personally, I get a lot of energy from innovating, and I love to be a part of overcoming the challenges that arise. I must be honest, when things become too much of a routine, in the end, my attention drifts away. That’s also one of the main reasons why I chose to accept this challenging position at our Groningen site.

How do you look at the science part of our business? 

Clients often reach out because they don’t have the knowledge, or sometimes they are even stuck on their project. This certainly makes it more interesting, since, for us, it means that the difficult challenges end up on our desks. That is also the reason why we can add lots of value for our clients by helping them to advance.

Where do you believe that Symeres can make a difference?

We as a company need to constantly find unique selling points in what we offer to our clients. From what I have seen so far, I think that we have lots of experience to offer and a very high scientific level. Adding it all up, I think that our outstanding scientists, great teamwork, and the open and pro-active communication style that we have, are our main differentiators.

Resources we think you'll love

Blog

Capacity Constraints and Resource Stretch

CDMO red flags you can’t ignore: Capacity constraints and resource stretch

Part 4: When “Too Busy” Becomes a Business Risk Even the most capable CDMO cannot deliver high-quality work if it is stretched too thin. As demand for outsourcing continues to rise across the life sciences sector, many CDMOs are operating near or beyond capacity. For pharma and biotech companies, this creates a silent but serious […]
View article

Blog

CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment

Part 3: Could Regulatory Misalignment Be Delaying Your Submission? A CDMO can have the best scientists, excellent facilities, and strong technical execution, yet still fall short when it comes to regulatory alignment. This disconnect between scientific performance and regulatory readiness is one of the most damaging red flags in drug development as it could delay […]
View article

Whitepaper

5 CDMO red flags you can’t ignore: A guide for biotechs and pharma

Selecting the right CDMO is one of the most important choices a biotech or pharma team will make. The right partner helps you move efficiently toward IND or IMPD, safeguard quality, and anticipate regulatory needs before they become roadblocks. The wrong one can mean delays, rising costs, and lost momentum. At Exemplify BioPharma, a Symeres company, […]
View article

Blog

CDMO red flags you can’t ignore: Underestimating technology transfer complexity

Part 2: Why “Scale-Up” Isn’t Just a Bigger Batch Transitioning a process from discovery scale to GMP manufacturing is almost never straightforward. What runs smoothly at 100 milligrams in the lab can behave very differently at the kilogram scale. Yet too many programs falter because the complexity of this transition is underestimated or treated as […]
View article

Blog

O.N.E Symeres: A practical approach to real-world drug development

No drug development program runs perfectly. Chemistry misbehaves, funding shifts, and timelines tighten. But what defines a reliable partner is how they respond. O.N.E Symeres is the framework we use to keep projects moving through uncertainty: openness, nimbleness, and expertise.
View article

Blog

CDMO red flags you can’t ignore: Undefined or shifting project scope

Part 1: Is an Undefined Scope Putting Your Project at Risk? Selecting the right CDMO is one of the most important decisions in drug development. Yet even experienced biotechs and pharma companies can find themselves trapped in projects where the initial excitement gives way to frustration, and one of the most common culprits is a […]
View article

Whitepaper

Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry

By combining automation, data-driven design, and deep synthetic expertise, Symeres is redefining how chemists generate and optimize compound libraries, bringing speed, scalability, and creativity to modern drug discovery.
View article

Webinar | On-demand

From racemic to pure the art and science of enantiomer separation

From the classical and Dutch resolution methods to preferential crystallization and deracemization, learn the best ways to obtain your desired purity!
View article

Whitepaper

IND & IMPD enabling developability roadmap

Drug discovery and development is a complex and iterative process that involves the identification, design, development, testing, and approval of new pharmaceutical drugs for use in patients. It encompasses a series of scientific, regulatory, and commercial activities aimed at discovering and bringing safe and effective medicines to the market. A key milestone in this process […]
View article

Whitepaper

Innovations in unnatural amino acids: Advancing functional diversity and applications

Unnatural amino acids enable groundbreaking advancements in drug discovery, biomaterials, and peptide design by introducing novel chemical functionalities that enhance stability, specificity, and bioactivity. This whitepaper highlights Symeres’ expertise in synthesizing unnatural amino acids, including side-chain modifications, N-functionalization, and cyclic variants, for applications in pharmaceuticals, diagnostics, and materials science. Utilizing advanced techniques like biocatalysis and […]
View article

Whitepaper

Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D

Our experience in overcoming scaleup challenges and harnessing the benefits of non-noble-metal catalysis makes Symeres the CRO of choice for challenging steps, such as the Ullmann reaction.
View article

Whitepaper

Managing nitrosamines in the pharmaceutical industry: A comprehensive approach

A comprehensive overview of nitrosamine risk assessment, including potential formation, scavenging, and analysis, is described here.
View article

Whitepaper

Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction

Here at Symeres, we have our new ‘Solid-State Center of Excellence’, and in this whitepaper we describe how we utilize our expertise and novel innovation to further our solid-state capabilities.
View article

Whitepaper

Stable isotope-labeled compounds

Discover how Symeres applies advanced synthetic chemistry and ADME expertise to design, produce, and study stable isotope-labelled compounds that enhance precision in drug development.
View article

Whitepaper

Unlocking the potential of high-throughput screening: Symegold library design and expansion insights

Learn how Symeres combines advanced chemistry platforms and deep discovery expertise to design and expand the SymeGold library, driving more efficient high-throughput screening and smarter hit identification.
View article

Interviews

Insights into drug discovery and development 2025

Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
View article

Interviews

Interview with the computer-aided drug design (CADD) department

Our Computer Aided Drug Design department supports our clients' drug discovery projects with some of the best (predictive) software.
View article

Interviews

Meet the Organix Director, Mario Gonzalez

We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.
View article

Interviews

An interview with Yadan Chen and Paul O’Shea

We are pleased to introduce the founders of Symeres’ daughter company Exemplify in New Jersey: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
View article

Interviews

An interview with Anu Mahadevan and Paul Blundell

We proudly introduce the founders of Symeres’ daughter company Organix in Boston: Anu Mahadevan, CEO, and Paul Blundell, President at Organix. Who are they? What do they stand for? And how does Organix fit with Symeres?
View article

Blog

Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same

Organix, a Symeres company, developed scale up conditions of the synthesis of 25-hydroxy cholesterol 3-monosulfate (sodium salt) from cholesterol. After the protection of the hydroxy group (acetate) and double bond (debromination), the hydroxy group in position 25 was introduced using oxone and trifluoromethylethylketone. Then the 3-hydroxy group and double bond were deprotected, and the resulting […]
View article

Webinar | On-demand

In vivo pharmacokinetic experiments in preclinical drug development

Despite a good part of ADME research in drug discovery and preclinical development can be performed using various in silico or in vitro systems, eventually it becomes necessary to evaluate the pharmacokinetic (PK) profile in animals to elucidate in vivo DMPK properties of the drug candidates.
View article

Webinar | On-demand

Accelerating medicinal chemistry by rapid analoging

Medicinal chemistry is the art of rapidly evolving initial hits to clinical candidates via smart, information driven multiparametric optimization.
View article

Webinar | On-demand

Solid-state chemistry part II: Optimal form selection by controlled crystallization

The webinar by Dr. Edwin Aret of Symeres focuses on advanced strategies for selecting and controlling solid forms of pharmaceutical compounds through crystallization techniques.
View article

Webinar | On-demand

Route scouting for kilogram-scale manufacturing of APIs

The webinar by Dr. Martin Strack provides an in-depth exploration of the strategies and considerations involved in developing scalable synthetic routes for Active Pharmaceutical Ingredients (APIs)
View article

Webinar | On-demand

Solid-state chemistry part I: Introduction

This webinar, presented by solid-state expert Edwin Aret, offers an insightful introduction to the field of solid-state chemistry.
View article

Speak with our experts

Let’s discuss how Symeres can support the discovery and development of your next breakthrough